792 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the 4th quarter, HoldingsChannel reports. The fund purchased 792 shares of the medical research company’s stock, valued at approximately $45,000.

Several other institutional investors have also recently made changes to their positions in the stock. Polar Asset Management Partners Inc. grew its stake in shares of Exact Sciences by 20.1% in the 4th quarter. Polar Asset Management Partners Inc. now owns 81,997 shares of the medical research company’s stock valued at $4,607,000 after buying an additional 13,697 shares during the period. Polar Capital Holdings Plc acquired a new stake in Exact Sciences in the fourth quarter valued at approximately $13,789,000. Quantinno Capital Management LP increased its holdings in shares of Exact Sciences by 205.4% during the fourth quarter. Quantinno Capital Management LP now owns 9,991 shares of the medical research company’s stock valued at $561,000 after acquiring an additional 6,720 shares in the last quarter. OMERS ADMINISTRATION Corp increased its holdings in shares of Exact Sciences by 1.1% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 121,044 shares of the medical research company’s stock valued at $6,801,000 after acquiring an additional 1,305 shares in the last quarter. Finally, Meridiem Capital Partners LP acquired a new position in shares of Exact Sciences during the fourth quarter worth approximately $11,358,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the subject of several research reports. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Robert W. Baird lifted their price objective on shares of Exact Sciences from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Evercore ISI upped their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Royal Bank of Canada raised their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the company a “sector perform” rating in a research report on Friday, May 2nd. Finally, Scotiabank boosted their price objective on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.90.

Exact Sciences Stock Up 0.4%

Shares of NASDAQ:EXAS opened at $56.42 on Monday. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a market capitalization of $10.64 billion, a PE ratio of -10.13 and a beta of 0.92. The business has a fifty day moving average price of $46.37 and a two-hundred day moving average price of $52.08. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. During the same quarter in the prior year, the business earned ($0.60) earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.